$22.72+0.16 (+0.73%)
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Assembly Biosciences, Inc. in the Healthcare sector is trading at $22.72 with a market capitalization of $487M. Wall Street consensus targets $48.75 (4 analysts), implying a +114.6% move over the next 12 months. The stock is currently 43% below its 52-week high of $39.71, remaining 21.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are i...
Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate
Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses. Gaggar describe
Market forces rained on the parade of Assembly Biosciences, Inc. ( NASDAQ:ASMB ) shareholders today, when the analysts...
We can readily understand why investors are attracted to unprofitable companies. Indeed, Assembly Biosciences...